Institute for Clinical and Economic Review - Peterson Health Technology Institute value assessment framework for digital health technologies
Digital health technologies (DHTs) are a broad and rapidly innovating class of interventions with distinctive pathways for development, regulatory approval, uptake and reimbursement. Given the unique nature of DHTs, existing value assessment frameworks and evidence standards for health technologies such as drugs and devices are not directly applicable. The value assessment framework presented here describes a conceptual model and associated methods to guide assessments of DHTs. The framework seeks to accomplish two goals: to set evidence standards that guide technology developers to generate robust evidence on their products; and to provide reviews that help organizations adopt high-impact DHTs with the strongest evidence for delivering improved clinical outcomes and cost savings. This assessment framework will serve as the roadmap for future evaluations of DHTs by the Institute for Clinical and Economic Review (ICER) and the Peterson Health Technology Institute (PHTI). We believe that all stakeholders will benefit from comprehensive and explicit standards of evidence on the different dimensions necessary to understand the value of DHTs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of comparative effectiveness research - 12(2023), 12 vom: 14. Dez., Seite e230154 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pearson, Steven D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Digital health technology |
|---|
| Anmerkungen: |
Date Completed 01.12.2023 Date Revised 23.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.57264/cer-2023-0154 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364575042 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364575042 | ||
| 003 | DE-627 | ||
| 005 | 20240423232023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.57264/cer-2023-0154 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1384.xml |
| 035 | |a (DE-627)NLM364575042 | ||
| 035 | |a (NLM)37965898 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pearson, Steven D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Institute for Clinical and Economic Review - Peterson Health Technology Institute value assessment framework for digital health technologies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.12.2023 | ||
| 500 | |a Date Revised 23.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Digital health technologies (DHTs) are a broad and rapidly innovating class of interventions with distinctive pathways for development, regulatory approval, uptake and reimbursement. Given the unique nature of DHTs, existing value assessment frameworks and evidence standards for health technologies such as drugs and devices are not directly applicable. The value assessment framework presented here describes a conceptual model and associated methods to guide assessments of DHTs. The framework seeks to accomplish two goals: to set evidence standards that guide technology developers to generate robust evidence on their products; and to provide reviews that help organizations adopt high-impact DHTs with the strongest evidence for delivering improved clinical outcomes and cost savings. This assessment framework will serve as the roadmap for future evaluations of DHTs by the Institute for Clinical and Economic Review (ICER) and the Peterson Health Technology Institute (PHTI). We believe that all stakeholders will benefit from comprehensive and explicit standards of evidence on the different dimensions necessary to understand the value of DHTs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a digital health technology | |
| 650 | 4 | |a health technology assessment | |
| 650 | 4 | |a value assessment framework | |
| 700 | 1 | |a Singh, Prabhjot |e verfasserin |4 aut | |
| 700 | 1 | |a Beaudoin, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Jon |e verfasserin |4 aut | |
| 700 | 1 | |a Schapiro, Lindsey |e verfasserin |4 aut | |
| 700 | 1 | |a Emond, Sarah K |e verfasserin |4 aut | |
| 700 | 1 | |a Pearson, Caroline |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of comparative effectiveness research |d 2012 |g 12(2023), 12 vom: 14. Dez., Seite e230154 |w (DE-627)NLM218708033 |x 2042-6313 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:12 |g day:14 |g month:12 |g pages:e230154 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.57264/cer-2023-0154 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 12 |b 14 |c 12 |h e230154 | ||